Article
Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation.
Future oncology (London, England) - 1 Jul 2020
Imamura Fumio, Kimura Madoka, Yano Yukihiro, Mori Masahide, Suzuki Hidekazu, Hirashima Tomonori, Ihara Shouichi, Komuta Kiyoshi, Shiroyama Takayuki, Nagatomo Izumi, Kumagai Toru
Abstract excerpt
Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer (NSCLC). As the hazards ratio of overall survival in comparison with first-generation EGFR-tyrosine kinase inhibitors was almost similar between FLAURA and ARCHER 1050, salvage use of osimertinib is still a treatment option. Patients & methods: We retrospectively analyzed the clinical courses of EGFR mutation-positive NSCLC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.